drugset / Trial / NCT04450732
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
Timeline
- Start
- 2020-07-07
- Primary completion
- 2024-03-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GQ1001 | Other / unclassified | 1.2 mg/kg | Intravenous |
| Subject | GQ1001 | Other / unclassified | 2.4 mg/kg | Intravenous |
| Subject | GQ1001 | Other / unclassified | 3.6 mg/kg | Intravenous |
| Subject | GQ1001 | Other / unclassified | 4.8 mg/kg | Intravenous |
| Subject | GQ1001 | Other / unclassified | 6 mg/kg | Intravenous |
| Subject | GQ1001 | Other / unclassified | 7.2 mg/kg | Intravenous |
| Subject | GQ1001 | Other / unclassified | 8.4 mg/kg | Intravenous |